| 초록 |
According to current guidelines, donor candidates with controlled hypertension using 1 or 2 antihypertensive drugs may be considered as donor. However, this recommendation is based on the study that antihypertensive drug was initiated in mainly “after donor registration” and this may be white-coat hypertension because of donation-related anxiety, therefore “using antihypertensive drugs” might be misinterpreted as if it includes the kidney donors using “previously” (before donor registration). We compared the follow-up estimated glomerular filtration rate (eGFR) between living kidney donors previously receiving antihypertensive drugs and matched controls. This single-center retrospective study classified 97 living kidney donors previously receiving antihypertensive drugs into two groups; 1 drug group (61 donors) and 2 drugs group (36 donors). We compared follow-up eGFR between each donor previously receiving antihypertensive drugs and 1:3 age-, sex-, and follow-up duration matched controls who did not receive antihypertensive drugs previously. There was no significant difference in follow-up GFR between donors previously taking antihypertensive drugs and matched controls in each group and in total donors. Among the total donors, there was no significant difference in the number of donors with eGFR≤45mL/min/1.73m2. Multiple linear regression analysis showed that baseline eGFR was the only independent risk factor for the final follow-up eGFR in the total donors. Our result supports the current guidelines that donor candidates with controlled hypertension using 1 or 2 antihypertensive drugs may be considered as donors, and may increase the strength of this recommendation. |